{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"365.26","value":"61037.57"},{"groupId":"OG001","spread":"305.31","value":"64705.82"},{"groupId":"OG002","spread":"156.23","value":"123460.33"},{"groupId":"OG003","spread":"174.22","value":"122228.99"},{"groupId":"OG004","spread":"83.19","value":"162706.00"},{"groupId":"OG005","spread":"99.44","value":"176233.64"},{"groupId":"OG006","spread":"234.07","value":"140331.08"},{"groupId":"OG007","spread":"128.25","value":"103009.98"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"20"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"24"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Cmax is the maximal concentration of JCARH125 CAR T cells in the blood after its infusion as determined by quantitative polymerase chain reaction (qPCR) to detect the JCARH125 transgene.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"JCARH125 IV at dose level 50 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 50 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 150 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG001","title":"Phase 1 150 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 300 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG002","title":"Phase 1 300 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 450 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG003","title":"Phase 1 450 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG004","title":"Phase 1 600 x 10^6 Cells"},{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG005","title":"Phase 1 Anakinra 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells expansion","id":"OG006","title":"Phase 2 600 x 10^6 Cells"},{"description":"JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells in participants previously treated with BCMA-directed anti-myeloma therapy","id":"OG007","title":"Phase 2a 600 x 10^6 Cells Anti-BCMA"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All participants who have the necessary PK measurements to provide interpretable results for this specific parameter of interest","reportingStatus":"POSTED","timeFrame":"From JCARH125 infusion through the day 29 visit","title":"Maximum Observed Concentration (Cmax)","type":"SECONDARY","unitOfMeasure":"Copies/UG"}